Tags

Type your tag names separated by a space and hit enter

Development of sustained-release matrix tablets of BKP-01-041 (tilorone derivative) containing Hypromellose.
Pharmazie. 2013 Oct; 68(10):796-9.P

Abstract

The objective of this research was to develop and evaluate sustained-release matrix tablets of BKP-01-041 (tilorone derivative) based on Hypromellose (hydroxypropyl methylcellulose, HPMC) as the matrix forming polymer. The sustained-release tablets were prepared by the wet granulation method. The influence of HPMC viscosity and ratios on drug release was investigated in vitro. Dissolution of the tablets developed with 26% HPMC K4 M/K100 M (1:2) (w/w) content showed a better drug release profile than the other batches tested in 12 h. Drug release from the optimal formulation was analyzed using release kinetics equations. The release kinetics parameters were determined and the value of the exponent (n) representing the apparent drug release mechanism determined from the Peppas equation was about 0.726. These results suggest that the drug release mechanism was non-Fickian (0.45 < n < 0.89), and drug release was dependent on both drug diffusion and polymer erosion.

Authors+Show Affiliations

Tianjin Medical University, No. 220, Dongting Road, 300 457 Tianjin, PR China. cliangmei@gmail.comNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24273882

Citation

Chen, Liangmei, and Fei Wang. "Development of Sustained-release Matrix Tablets of BKP-01-041 (tilorone Derivative) Containing Hypromellose." Die Pharmazie, vol. 68, no. 10, 2013, pp. 796-9.
Chen L, Wang F. Development of sustained-release matrix tablets of BKP-01-041 (tilorone derivative) containing Hypromellose. Pharmazie. 2013;68(10):796-9.
Chen, L., & Wang, F. (2013). Development of sustained-release matrix tablets of BKP-01-041 (tilorone derivative) containing Hypromellose. Die Pharmazie, 68(10), 796-9.
Chen L, Wang F. Development of Sustained-release Matrix Tablets of BKP-01-041 (tilorone Derivative) Containing Hypromellose. Pharmazie. 2013;68(10):796-9. PubMed PMID: 24273882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of sustained-release matrix tablets of BKP-01-041 (tilorone derivative) containing Hypromellose. AU - Chen,Liangmei, AU - Wang,Fei, PY - 2013/11/27/entrez PY - 2013/11/28/pubmed PY - 2014/1/17/medline SP - 796 EP - 9 JF - Die Pharmazie JO - Pharmazie VL - 68 IS - 10 N2 - The objective of this research was to develop and evaluate sustained-release matrix tablets of BKP-01-041 (tilorone derivative) based on Hypromellose (hydroxypropyl methylcellulose, HPMC) as the matrix forming polymer. The sustained-release tablets were prepared by the wet granulation method. The influence of HPMC viscosity and ratios on drug release was investigated in vitro. Dissolution of the tablets developed with 26% HPMC K4 M/K100 M (1:2) (w/w) content showed a better drug release profile than the other batches tested in 12 h. Drug release from the optimal formulation was analyzed using release kinetics equations. The release kinetics parameters were determined and the value of the exponent (n) representing the apparent drug release mechanism determined from the Peppas equation was about 0.726. These results suggest that the drug release mechanism was non-Fickian (0.45 < n < 0.89), and drug release was dependent on both drug diffusion and polymer erosion. SN - 0031-7144 UR - https://www.unboundmedicine.com/medline/citation/24273882/Development_of_sustained_release_matrix_tablets_of_BKP_01_041__tilorone_derivative__containing_Hypromellose_ DB - PRIME DP - Unbound Medicine ER -